Symptom Severity and Treatment Satisfaction in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)
Open Access
- 1 March 2023
- journal article
- research article
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 15, 89-101
Abstract
Objective: Idiopathic hypersomnia is a debilitating sleep disorder characterized by excessive daytime sleepiness, sleep inertia, and prolonged sleep duration. The patient burden of idiopathic hypersomnia is poorly understood. The Real World Idiopathic Hypersomnia Outcomes Study (ARISE) evaluated symptoms and treatment effectiveness/satisfaction in participants with idiopathic hypersomnia. Methods: ARISE was a United States–based virtual cross-sectional survey. Participants were adults 21– 65 years of age with idiopathic hypersomnia recruited from social media, the Hypersomnia Foundation website, and a patient panel. Self-assessments included the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Treatment Satisfaction Questionnaire for Medication, version II (TSQM-vII), and additional treatment questions. Data were analyzed for all participants and for subgroups with/without long sleep time (LST; ≥ 11 hours in 24 hours). Results: Of 75 participants enrolled, most were female (81.3%). The mean (SD) age was 34.1 (10.7) years and 49% had LST. Most participants took off-label prescription medications (89.3%) and/or used other measures (93.3%) to manage their symptoms. The mean (SD) ESS score was 14.5 (3.5) and the mean IHSS score was 35.2 (7.6). Treatment satisfaction was low (mean [SD] TSQM-vII score: overall, 61.9 [21.2]; with LST, 57.9 [21.4]; without LST, 66.7 [20.3]), primarily driven by dissatisfaction with treatment effectiveness. The most common classes of prescription medications used were stimulants (61.3%), wake-promoting agents (28.0%), and antidepressants (18.7%); non-prescription measures used to manage symptoms included caffeine (73.3%), planned naps (34.7%), and individual accommodations (32.0%). Conclusion: Overall, participants with idiopathic hypersomnia, with or without LST, had substantial symptom burden despite most of the study population taking off-label medications and using nonprescription measures to manage symptoms.Keywords
This publication has 27 references indexed in Scilit:
- Idiopathic hypersomniaSleep Medicine Reviews, 2016
- Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey StudyBehavioral Sleep Medicine, 2016
- Car Crashes and Central Disorders of Hypersomnolence: A French StudyPLOS ONE, 2015
- Modafinil in the treatment of idiopathic hypersomnia without long sleep time—a randomized, double‐blind, placebo‐controlled studyJournal of Sleep Research, 2014
- Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepinessJournal of Sleep Research, 2010
- Idiopathic Hypersomnia: Clinical Features and Response to TreatmentJournal of Clinical Sleep Medicine, 2009
- Psychological health in central hypersomnias: the French Harmony studyJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among Outpatient Pharmacy ConsumersValue in Health, 2005
- Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth and Quality of Life Outcomes, 2004
- Declaring the Sodium Content of Drug ProductsNew England Journal of Medicine, 1995